Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
Altamira Therapeutics announced the dissemination of positive results from its NASAR clinical trial for Bentrio nasal spray in treating seasonal allergic rhinitis (SAR). The trial's results, published in the Allergy journal's social media channels, showed significant efficacy and safety. The study, involving 100 patients in Australia, met its primary endpoint by significantly reducing the mean daily reflective Total Nasal Symptom Score (rTNSS) compared to saline (p = 0.013). Secondary endpoints also showed significant improvements in quality of life and global efficacy ratings (p < 0.001). Altamira expects Bentrio's sales to grow significantly with planned launches in new markets in 2024.
- The NASAR trial met its primary efficacy endpoint, showing a significant reduction in mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013).
- Secondary efficacy endpoints showed significant improvement in health-related quality of life (p < 0.001) and superior global ratings of efficacy (p < 0.001).
- Bentrio demonstrated good safety and tolerability similar to saline, with fewer patients requiring relief medication.
- The results were disseminated through Allergy's social media channels, reaching over 250,000 readers monthly.
- Altamira expects significant sales growth for Bentrio from 2024, driven by launches in additional countries and new distribution partnerships in key markets like the US and Europe.
- The press release did not mention specific financial figures or revenue impacts from the positive trial results, leaving uncertainty about immediate financial benefits.
- The reliance on social media channels for disseminating trial results, while extensive, may not have the same impact as traditional publication methods in medical journals.
- No information on regulatory approvals or timelines for launching Bentrio in new markets, which could delay expected sales growth.
The NASAR trial results for Bentrio nasal spray in seasonal allergic rhinitis (SAR) represent a positive development for Altamira Therapeutics. The trial, which included 100 patients, demonstrated a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to a saline spray (
The dissemination of the trial results through social media channels of 'Allergy,' a leading journal, taps into a broad professional audience, which could foster stronger market acceptance and adoption of Bentrio. Allergy's extensive reach, boasting over 250,000 readers monthly and generating two million article downloads annually, ensures visibility among key stakeholders, including healthcare professionals and potential distributors. This heightened awareness can translate into faster market penetration, especially as Altamira Medica plans to expand Bentrio's availability in new markets. The strategic choice of leveraging social media for dissemination is likely to enhance the brand's credibility and appeal, aligning with modern, digital consumption of medical content.
From a financial perspective, Altamira's projections for significant sales growth from 2024, driven by the launch of Bentrio in additional countries, indicate potential revenue uplift. The positive clinical trial outcomes and subsequent dissemination could attract new partnerships and distributor agreements, important for expanding market reach. Investors should note the implications for Altamira's revenue streams, particularly if Bentrio secures strong market positions in the US, Europe and other key markets. The successful trial also positions Altamira to leverage further development in their RNA delivery technology, potentially opening new revenue avenues and enhancing investor confidence in the company's growth trajectory.
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that highlights from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR) have been published in video format on the social media channels of Allergy, one of the highest-ranking journals in the field of allergology world-wide. This follows the journal’s publication in April of the peer-reviewed article “AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial” which had provided detailed information about this pivotal trial. The video abstract is presented by Sven Becker, MD, the first author of the publication, and it is accessible via:
YouTube: https://www.youtube.com/watch?v=Om8suFiQGcg&ab_channel=Allergy
Facebook: https://www.facebook.com/EAACIAllergy
Twitter: https://twitter.com/AllergyEaaci
LinkedIn: https://www.linkedin.com/company/allergy-eaaci
Allergy’s social media reaches out to over 250’000 readers every month, and there are more than two million downloads of their articles per year.
The NASAR trial enrolled 100 patients during allergy season in Australia who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray, the current standard of care in drug-free SAR management. Study participants self-administered the treatment for two weeks three times per day. The study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013), as well as its secondary efficacy endpoints. The latter included, among others, a statistically significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001). In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment.
“We are delighted to see the great results from the NASAR trial shared by Allergy, one the leading medical journals in allergology, with a large audience through its social media channels,” commented Thomas Meyer, Altamira’s founder, Chairman, and CEO. “The concept of Bentrio as a drug-free and preservative-free spray forming an efficient protective barrier within the nasal cavity appears to resonate well with allergic rhinitis sufferers. We look forward to making the product available in additional countries and helping more patients deal with the daily burden and discomfort associated with allergic rhinitis.”
Bentrio is marketed by Altamira Medica AG, an associate company of Altamira Therapeutics, primarily through distributors. From 2024 onwards, Altamira Medica expects sales to grow significantly, mainly driven by the launch of Bentrio in additional countries. The Company expects to conclude partnering discussions and negotiations for distribution in the US, Europe and other key markets in the course of 2024.
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
Forward-Looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the success of strategic transactions, including licensing or partnering, with respect to Altamira’s legacy assets, Altamira’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the clinical utility of Altamira’s product candidates, the timing or likelihood of regulatory filings and approvals, Altamira’s intellectual property position and Altamira’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira’s Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira’s other filings with the Securities Exchange Commission (“SEC”), which are available free of charge on the SEC’s website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira or to persons acting on behalf of Altamira are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor Contact:
FAQ
What were the primary outcomes of the NASAR trial for Bentrio nasal spray?
How did Bentrio perform in terms of safety and tolerability?
What are the future sales expectations for Bentrio nasal spray?
Where was the NASAR trial result for Bentrio published?
What secondary efficacy endpoints did the NASAR trial achieve?
